Overview
The author interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views on their current application within non-small cell lung cancer (NSCLC), and the potential broader development of immuno-oncology approaches and biomarkers within the indication.
The author interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views on their current application within non-small cell lung cancer (NSCLC), and the potential broader development of immuno-oncology approaches and biomarkers within the indication.
